Research Article
Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy
Table 4
Factors related to the improvement of eGFR (CKD-EPI) (increase in eGFR > 10%) according to univariate and multivariate logistic regressions.
| Risk factor | Univariate | value | Multivariate | value | HR (95% CI) | HR (95%CI) |
| Age: ≥50 years | 2.221 (1.070–4.611) | 0.032 | 1.315 (0.576–3.001) | 0.516 | Sex: male | 0.987 (0.423–2.305) | 0.976 | | | HBeAg: positive | 0.663 (0.308–1.427) | 0.293 | | | Cirrhosis | 0.785 (0.333–1.849) | 0.580 | | | Decompensation | 0.929 (0.342–2.520) | 0.885 | | | Hepatocellular carcinoma | 1.101 (0.338–3.583) | 0.873 | | | HBV genotype: type B | 0.518 (0.222–1.209) | 0.128 | | | Baseline ALT > 200 U/L | 1.031 (0.494–2.154) | 0.935 | | | Baseline HBV DNA: <7 log IU/mL | 1.222 (0.564–2.650) | 0.611 | | | Baseline eGFR < 60 mL/min/1.73 m2 | 7.117 (1.849–27.399) | 0.004 | 4.560 (1.046–19.875) | 0.043 | Diabetes mellitus | 5.958 (1.776–19.993) | 0.004 | 4.194 (1.165–15.098) | 0.028 | Hypertension | 0.931 (0.436–3.874) | 0.864 | | | Add-on adefovir therapy | 0.477 (0.186–1.222) | 0.123 | | | Complete virological response at month 6 | 1.670 (0.778–3.585) | 0.189 | | | Contrast medium exposure | 1.101 (0.338–3.583) | 0.873 | | |
|
|
ALT: alanine transaminase; HBeAg: hepatitis B e-antigen; HR: hazard ratio.
|